Stifel Nicolaus Has Lowered Expectations for Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price

Eyepoint Pharmaceuticals (NASDAQ:EYPT) had its price objective lowered by equities researchers at Stifel Nicolaus from $6.00 to $5.00 in a research report issued on Friday, Benzinga reports. The firm presently has a “buy” rating on the stock.

EYPT has been the topic of several other research reports. Wall Street Zen upgraded Eyepoint Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Sunday, September 27th. Citigroup reduced their price objective on shares of Eyepoint Pharmaceuticals to $17.00 and set a “buy” rating for the company in a research note on Tuesday, August 18th. JPMorgan Chase & Co. cut shares of Eyepoint Pharmaceuticals from a “neutral” rating to an “underweight” rating in a report on Tuesday, October 20th. Guggenheim downgraded shares of Eyepoint Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Monday, October 19th. Finally, Mizuho downgraded shares of Eyepoint Pharmaceuticals from an “outperform” rating to a “neutral” rating and set a $0.50 target price on the stock. in a research report on Tuesday, October 20th. Two research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $18.35.

Eyepoint Pharmaceuticals Stock Down 10.4%

Shares of NASDAQ EYPT opened at $0.32 on Friday. The stock’s fifty day simple moving average is $2.41 and its 200 day simple moving average is $10.32. The stock has a market capitalization of $27.54 million, a price-to-earnings ratio of -0.09 and a beta of 1.84. Eyepoint Pharmaceuticals has a 52-week low of $0.31 and a 52-week high of $19.11.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its earnings results on Thursday, November 12th. The company reported ($1.07) EPS for the quarter, missing the consensus estimate of ($0.93) by ($0.14). Eyepoint Pharmaceuticals had a negative net margin of 10,994.73% and a negative return on equity of 135.81%. The company had revenue of $0.76 million for the quarter, compared to analysts’ expectations of $0.23 million. As a group, analysts anticipate that Eyepoint Pharmaceuticals will post -3.46 earnings per share for the current year.

Institutional Investors Weigh In On Eyepoint Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. KBC Group NV purchased a new position in Eyepoint Pharmaceuticals during the 1st quarter valued at about $29,000. Integrated Wealth Concepts LLC purchased a new stake in shares of Eyepoint Pharmaceuticals in the second quarter worth approximately $72,000. Engineers Gate Manager LP acquired a new stake in shares of Eyepoint Pharmaceuticals during the second quarter worth approximately $161,000. Janney Montgomery Scott LLC boosted its holdings in shares of Eyepoint Pharmaceuticals by 14.8% during the first quarter. Janney Montgomery Scott LLC now owns 30,315 shares of the company’s stock worth $391,000 after purchasing an additional 3,900 shares during the period. Finally, Levin Capital Strategies L.P. boosted its holdings in shares of Eyepoint Pharmaceuticals by 65.8% during the first quarter. Levin Capital Strategies L.P. now owns 31,500 shares of the company’s stock worth $406,000 after purchasing an additional 12,500 shares during the period. 99.41% of the stock is currently owned by institutional investors and hedge funds.

About Eyepoint Pharmaceuticals

EyePoint Pharmaceuticals is a biopharmaceutical company focused on developing treatments for serious eye diseases. Its drug-delivery technology is designed to provide sustained release of medication in the eye, with the goal of reducing the need for frequent injections or other repeated treatments. The company’s pipeline includes DURAVYU, an investigational sustained-release treatment being studied for retinal conditions including wet age-related macular degeneration and diabetic retinopathy. EyePoint previously developed and marketed ophthalmic products including YUTIQ and DEXYCU, and sold those commercial assets to Alimera Sciences in 2023.